RESULTS	In the omalizumab group ( n = 14 ) , a significant decrease in the percentage of sputum eosinophils ( p < 0.01 ) , improved forced expiratory volume in 1 s ( FEV ( 1 ) ) , and an improved AQLQ score were recorded .\